Cullen Capital Management’s Novo Nordisk NVO Stock Holding History

Cullen Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.7M	Buy	1,224,955 +432,600	+55%	+$18.6M	0.58%	57
2026 Q1	$29.1M	Buy	792,355 +244,835	+45%	+$11.6M	0.3%	75
2025 Q4	$27.9M	Buy	+547,520	New	+$28M	0.3%	74
2018 Q4	–	Sell	-119,020	Closed	-$2.81M	–	129
2018 Q3	$2.81M	Sell	119,020 -2,680	-2%	-$65.4K	0.1%	84
2018 Q2	$2.81M	Buy	121,700 +3,360	+3%	+$79.9K	0.11%	91
2018 Q1	$2.91M	Buy	118,340 +2,780	+2%	+$73K	0.1%	95
2017 Q4	$3.1M	Sell	115,560 -4,760	-4%	-$121K	0.11%	99
2017 Q3	$2.9M	Buy	120,320 +84,760	+238%	+$1.92M	0.1%	99
2017 Q2	$763K	Sell	35,560 -1,640	-4%	-$33.1K	0.03%	115
2017 Q1	$638K	Hold	37,200	–	–	0.02%	132
2016 Q4	$667K	Buy	+37,200	New	+$674K	0.02%	131

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cullen Capital Management's NVO Position: Q2 2026 in Review

Cullen Capital Management increased its Novo Nordisk (NVO) stake by 55% in Q2 2026, buying an estimated $18.6M and bringing the position to 1,224,955 shares worth $58.7M. The position accounts for 0.58% of the portfolio, ranked #57.

Cullen Capital Management first reported a position in NVO in Q4 2016 and has held it in 11 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Cullen Capital Management held 1,224,955 shares of Novo Nordisk worth $58.7M as of Q2 2026.
Cullen Capital Management bought 432,600 Novo Nordisk shares in Q2 2026, an estimated $18.6M.
Novo Nordisk made up 0.58% of Cullen Capital Management's portfolio in Q2 2026, its #57 holding.
Cullen Capital Management first reported a position in Novo Nordisk in Q4 2016 and has held it in 11 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cullen Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.